US 12,343,344 B2
Pharmaceutical combination comprising TNO155 and ribociclib
Ying-Nan Pan Chen, Wilmington, DE (US); Huaixiang Hao, Lexington, MA (US); Chen Liu, Wayland, MA (US); and Morvarid Mohseni, Boston, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Appl. No. 17/430,219
Filed by NOVARTIS AG, Basel (CH)
PCT Filed Feb. 10, 2020, PCT No. PCT/IB2020/051031
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/165734, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/804,708, filed on Feb. 12, 2019.
Prior Publication US 2022/0160707 A1, May 26, 2022
Int. Cl. A61K 31/497 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/497 (2013.01) [A61K 31/519 (2013.01); A61P 35/00 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A method of treating cancer comprising administering to a subject in need thereof comprising (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio) pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro [4.5]decan-4-amine, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent,
wherein the second therapeutic agent is the CDK4/6 inhibitor 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl) pyridin-2-yl)amino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxamide, or a pharmaceutically acceptable salt thereof;
wherein the cancer is selected from the group consisting of esophageal or head and neck squamous cell carcinoma; colorectal or non-small cell lung cancer; and renal cell carcinoma; and
wherein the amount of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio) pyrazin-2-y)-3-methyl-2-oxa-8-azaspiro [4.5]decan-4-amine, or a pharmaceutically acceptable salt thereof, and the amount of the second therapeutic agent administered to the subject in need thereof are effective to treat the cancer.